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China is experiencing increased health care use and expenditures, without sufficient controls to ensure quality and
value. Transparent, cost-conscious and patient-centered guidelines based on the best available evidence could help
establishing these quality and practice measures.
We examined how guidelines could support the Chinese health reform. Specifically, we summarized the current
state of the art and related challenges in guideline development and explored possible solutions in the context of
the Chinese health reform.
China currently lacks capacity for evidence-based guideline development and coordination by a central agency.
Most Chinese guideline users rely on recommendations developed by professional groups that lack demonstration
of transparency (including conflict of interest management and evidence synthesis) and quality. These deficiencies
appear larger than in other regions of the world. In addition, misperceptions about the role of guidelines in
assisting practitioners as opposed to providing rules requiring adherence, and a perception that traditional Chinese
medicine (TCM) cannot be appropriately incorporated in guidelines are present.
China’s capacity could be strengthened by a central guideline agency to provide or coordinate evidence synthesis
for guideline development and to oversee the work of guideline developers. China can build on what is known
and work with the international community to develop methods to meet the challenges of evidence-based
guideline development.China’s health care challenges in the context of
guideline development
In his opening remarks to an international symposium
on guideline development, Prof. YinDakui, former Chinese
Vice Minister of Health and now president of the Chinese
Association of Medical Doctors, stated that “all medical
practitioners in China should learn about and apply high-
quality evidence-based guidelines to practice in order to
make contributions to the health of people in China as
well as the world”. But how can this vision become reality?
The authors of this article organized an international con-
ference and brought together leading scientists in evidence
synthesis and Chinese health policy to examine how
guidelines could support the Chinese health reform. In* Correspondence: schuneh@mcmaster.ca
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reproduction in any medium, provided the orthis article, together with the conference speakers, we
summarize the current state of the art and related chal-
lenges in guideline development and explored possible
solutions in Lanzhou, China, on May 28 and 29, 2012,
specifically in the context of the Chinese health reform.
China is experiencing increased health care use and
expenditures, without sufficient controls to ensure qua-
lity and value. For example, between 2003 and 2011, the
insurance coverage increased from 30% to 96% and the
average share of inpatient costs reimbursed from insu-
rance increased from 14 to 47. There has been concern
about rising of cost and the Ministry of Health of China
called for a control of medical expenses in 2012[1]. Mea-
sures and instruments of care delivery such as rates of
caesarian sections, access to essential medicines and
independent evaluation of health care services are im-
portant but insufficient as indicators to monitor quantity
and quality of care provided. For example, WHO reported
that China has the world's highest rate of caesariand. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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necessary [2,3]. However, these measures do not cover the
entire spectrum of care and allowing care providers to
concentrate on a few selected measures rather than estab-
lishing best practice broadly could mean ignoring other
areas of health care delivery, in particular in large coun-
tries like China. Transparent, cost-conscious and patient-
centered guidelines based on the best available evidence
could help establishing these quality and practice mea-
sures and contain resource expenditure. In fact, guidelines
are becoming an important part of national health care
reforms in China because they may reduce health care
inequities and improve the quality of medical care.
Who might develop guidelines in China?
Ideally, guidance in China would be provided by national
agencies in collaboration with other stakeholders, including
practitioners, public health experts, the public. Western
countries can provide examples, e.g. the National Institute
of Health and Clinical Excellence (NICE) in the UK. How-
ever, given the Chinese context of TCM, local variations
in the implementation of the health reform, and the
massive size of the population, adaptation of such models
is needed that may require close collaboration between
central and regional government, academia, professional
associations and local health care leaders while ensuring
the highest possible level of transparency. Despite these
challenges, China can take advantage of the work that has
been performed by many guideline developers, team up
with these organizations and take advantage of organiza-
tions like the guideline international network (GIN).
State of the art of guideline development
According to the World Health Organisation’s definition,
appropriately developed guidelines, based on the best
available evidence, should assist providers and recipients
of health care and other stakeholders to make informed
decisions. Recommendations [in guidelines] may relate
to clinical interventions, public health activities, or go-
vernment policies [4]. International standards for the
development of such guidelines are available and they
agree on many key points such as question definition,
using credible and valid systematic reviews, grading of
evidence and strength of recommendations and manage-
ment of conflict of interest [5-7]. These standards have
become more stringent over time, because of research on
new methods and conceptual work in guideline develop-
ment, for example in the area of managing conflict of
interest. Despite the progress in defining criteria for trust-
worthy guideline development, gaps in research around
guideline group composition and processes, determining
and implementing criteria for moving from evidence
to recommendations and developing recommendations
about diagnostic tests and strategies are apparent. Thus,China can build on what is known and work with the
international community to develop methods to meet the
challenges of evidence-based guideline development.
Guidelines in China: status quo
China currently lacks capacity for evidence-based guide-
line development and coordination by a central agency.
Most Chinese guideline users rely on recommendations
developed by professional groups that lack demonstration
of transparency (including conflict of interest management
and evidence synthesis) and quality. These deficiencies ap-
pear larger than in other regions of the world [8,9]. As of
June 2012, the Guidelines International Network (G-I- N)
database lists more than 7200 guidelines (http://www.g-i-n.
net/library) and the National Guideline Clearinghouse
(NGC) contains about 2300 (http://www.guideline.gov).
However, no guideline from mainland of China is docu-
mented in either of these databases. There is no specific
organizational structure that supports clinical trials, sys-
tematic reviews and guideline development. In addition,
conference attendees witnessed misperceptions about the
role of guidelines in assisting practitioners as opposed to
providing rules requiring adherence, and a perception that
traditional Chinese medicine (TCM) cannot be appropri-
ately incorporated in guidelines. These concerns stem from
the belief that TCM is based on centuries of observations
and the holistic concept of TCM that cannot be reevalu-
ated or appropriately assessed in research studies that
reduce bias. Proper research designs could however
be employed to either summarize what is known or plan
studies that avoid bias.
Possible solutions to the challenges
China’s capacity could be strengthened by a central guide-
line agency to provide or coordinate evidence synthesis
for guideline development and to oversee the work of
guideline developers. A central health technology assess-
ment unit, a China NICE, the Chinese Cochrane Center
or the Chinese GRADE center could support or fulfill
such a role [10]. If progress can be made, Chinese guide-
line developers can adopt approaches that make guidelines
trustworthy and they can conduct research on best guide-
line development practices. Registration and certification
for guideline developers to adhere to minimal standards in
evidence assessment and transparent development and
reporting of recommendations [11,12], and monitoring
with tools such as AGREE [13] are steps that can avoid
duplication and ensure credibility of guidelines. China
can share evidence (both data and evidence syntheses)
and support capacity building in guideline develop-
ment through international collaborations. But equally
important are national collaborations, between guideline
developers, health policy makers and media to publish
guidelines that are developed to allow user-friendly
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cation about the intended purpose and use of guidelines
focusing on patient centered care will be central in mo-
ving forward. Finally, public access at all levels to guide-
lines through central (financial) support will allow for
greater guideline availability.
Conclusions
China has an excellent opportunity to build on experi-
ence of international guideline development efforts,
avoid the mistakes they made and set an example for
other emerging countries. We advocate that for all guide-
lines, the development process should be transparent
leading to actionable recommendations and advocate for
patients’ interests by acknowledging their preferences and
values. It could mean the beginning of a new era for health
care in China.
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